Using N-terminal pro-B-type natriuretic peptide to diagnose cardiac abnormalities in children with dyspneaen with dyspnea

Zakaria Mukalla; Ria Nova; Legiran Legiran; Yangtjik Yangtjik

doi:10.14238/pi57.3.2017.124-8

Zakaria Mukalla Department of Child Health, Sriwijaya University Medical School, Palembang, South Sumatera
Ria Nova Department of Child Health, Sriwijaya University Medical School, Palembang, South Sumatera
Legiran Legiran The Medical Research Center, Sriwijaya University Medical School, Palembang, South Sumatera
Yangtjik Yangtjik Department of Child Health, Sriwijaya University Medical School, Palembang, South Sumatera

DOI: https://doi.org/10.14238/pi57.3.2017.124-8

Keywords: NT-proBNP, dyspnea, cardiac abnormality

Abstract

Background. Dyspnea could be caused by various reason, one of which is the presence of cardiac abnormality. Physical examination sometimes difficult to distinguish breath caused by heart abnormalities, especially small children, so we need another way to find out.

Objective. To evaluate whether the examination of NT-proBNP levels can be used as a screening tool to diagnose cardiac abnormality in children presenting with dyspnea.

Methods. A Cross sectional study was conducted from August to October 2015 on pediatric patients aged 1 month to 18 years presenting with dyspnea in pediatric ward Mohammad Hoesin Hospital Palembang. All subjects performed blood sampling for NT-proBNP examination and echocardiography to assess the presence of cardiac abnormalities. The diagnostic value analyzed by ROC curve, and determined the optimal cut-off point, sensitivity and specificity.

Â Result. We obtained 58 subjects with median age 9.5 (1-180) months, consisted of 39 subjects with cardiac abnormalities and 19 subjects without cardiac abnormality. There is a significant difference (p = 0.002) of NT-proBNP levels in both groups with a medianÂ 1,775 (189-9,000) pg/ml vs 759 (245-9,000) pg/ml. In ROC curve analysis, AUC value was 0.75, and at the optimal cut-off point 1,235 pg/ml, sensitivity was 74.4% and specificity was 73.7%.

Conclusion. The level of NT-proBNP can be used to diagnose cardiac abnormalities in children presenting with dyspnea.

References

1. Krupicka J, Janota T, Kasalova Z, Hradec J. Natriuretic peptide â€“ physiology, pathophysiology and clinical use in heart failure. Physiol Res. 2009;58:171-7.
2. Geiger R, Hammerer-Lercher A, Url C, Schweigmann U, Puschendorf B, Sommer R, et al. NT-proBNP concentrations indicate cardiac disease in pediatric patients. Int J Cardiol. 2007;123:63-5.
3. Moses EJ, Mokhtar SAI, Hamzah A, Abdullah BS, Yusoff NM. Usefulness of N-terminal-pro-B-type natriuretic peptide as a screening tool for identifying pediatric patients with congenital heart disease. Lab Medicine. 2011;42:75-80.
4. Sharma M, Nair M, Jatana SK, Shahi BN. Congestive heart failure in infants and children. Med J Armed Forces India. 2003;59:229-33.
5. Yang S, Li L, Cao J, Yu H, Xu H. The differential diagnostic value of serum NT-proBNP in hospitalized patients of heart failure with pneumonia. J Clin Lab Anal. 2015;29:37-42.
6. Cohen S, Springer C, Avital A, Perles Z, Rein AJ, Argaman Z, et al. Amino-terminal pro-brain-type natriuretic peptide: heart or lung disease in pediatric respiratory distress? Pediatrics. 2005;115:1347-50.
7. Maher KO, Reed H, Cuadrado A, Simsic J, Mahle WT, DeGuzman M, et al. B-type natriuretic peptide in the emergency diagnosis of critical heart disease in children. Pediatrics. 2008;121:1484-8.
8. Hammerer-Lercher A, Geiger R, Mair J, Url C, Tulzer G, Lechner E, et al. Utility of N-terminal pro-B-type natriuretic peptide to differentiate cardiac diseases from noncardiac disease in young pediatric patients. Clin Chem. 2006;52:1415-9.
9. Nybo M, Benn M, Mogelvang R, Jensen JS, Schnohr P, Rehfeld JF, et al. Impact of hemoglobin on plasma pro-B-type natriuretic peptide concentrations in the general population. Clin Chem. 2007;53:1921-7.
10. Goetze JP, Gore A, Moller H, Steinbruchel DA, Rehfeld JF, Nielsen LB. Acute myocardial hypoxia increases BNP gene expression. FASEB J. 2004;18:1928-30.
11. Spaneus KS, von Eckardstein A. Natriuretic peptides in cardiac and renal failure. Pipette. 2007;6:6-11.
12. Ma KK, Ogawa T, de Bold AJ. Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase. J Mol Cell Cardiol. 2004;36:505-13.
13. Tsai SH, Lin YY, Chu SJ, Hsu CW, Cheng SM. Interpretation and use of natriuretic peptides in non-congestive heart failure settings. Yonsei Med J. 2010;51:151-63.
14. Berendes E, Walter M, Cullen P, Prien T, Van Aken H, Horsthemke J, et al. Secretion of brain natriuretic peptide in patients with aneurysmal subarachnoid haemorrhage. Lancet. 1997;349:245-9.
15. Levin ER, Gardner DG, Samson WK. Natriuretic peptides. N Engl J Med. 1998;339:321-8.
16. Nevo I, Erlichman M, Algur N, Nir A. N-terminal pro-B-type natriuretic peptide levels in infants and children with acute non-cardiac disease. Isr Med Assoc J. 2011;13:420-5.
17. Elsharawy S, Hassan B, Morsy S, Khalifa N. Diagnostic value of n-terminal pro-brain natriuretic peptide levels in pediatric patients with ventricular septal defect. Egypt Heart J. 2012;64:241-6.